Lyra Therapeutics, Inc.
LYRA
Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company'sā¦ read more
Healthcare
Biotechnology
5 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$3.80
Price+5.26%
$0.19
1Y
Price
Market Cap
$6.745m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-23524.0%
EBITDA Margin-23936.0%
Net Profit Margin-29444.0%
Free Cash Flow Margin-23524.0%
EBITDA Margin-23936.0%
Net Profit Margin-29444.0%
Free Cash Flow MarginRevenue
$600k
-60.9%
1y CAGR-16.0%
3y CAGR+82.5%
5y CAGREarnings
-$32.947m
+64.7%
1y CAGR+0.8%
3y CAGR-6.2%
5y CAGREPS
-$9.19
-542.7%
1y CAGR-175.0%
3y CAGR-119.9%
5y CAGRBook Value
-$4.328m
$43.709m
Assets$48.037m
Liabilities$31.379m
DebtDebt to Assets
71.8%
-1x
Debt to EBITDAFree Cash Flow
-$34.107m
+52.9%
1y CAGR-2.4%
3y CAGR-14.1%
5y CAGRNo items found.
Press Releases
Statements and updates from the company